A deep attention-based encoder for the prediction of type 2 diabetes longitudinal outcomes from routinely collected health care data
Year: 2025
Type: article
Abstract: Recent evidence indicates that Type 2 Diabetes Mellitus (T2DM) is a complex and highly heterogeneous disease involving various pathophysiological and genetic pathways, which presents clinicians with challenges in disease management. While deep learning models have made significant progress in helping practitioners manage T2DM treatments, several important limitations persist. In this paper we propose DARE, a model based on the transformer encoder, designed for analyzing longitudinal heterogeneous diabetes data. The model can be easily fine-tuned for various clinical prediction tasks, enabling a computational approach to assist clinicians in the management of the disease. We trained DARE using data from over 200,000 diabetic subjects from the primary healthcare SIDIAP database, which includes diagnosis and drug codes, along with various clinical and analytical measurements. After an unsupervised pre-training phase, we fine-tuned the model for predicting three specific clinical outcomes: i) occurrence of comorbidity, ii) achievement of target glycaemic control (defined as glycated hemoglobin < 7%) and iii) changes in glucose-lowering treatment. In cross-validation, the embedding vectors generated by DARE outperformed those from baseline models (comorbidities prediction task AUC = 0.88, treatment prediction task AUC = 0.91, HbA1c target prediction task AUC = 0.82). Our findings suggest that attention-based encoders improve results with respect to different deep learning and classical baseline models when used to predict different clinical relevant outcomes from T2DM longitudinal data.
Source: Expert Systems with Applications
Institutions: Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Institut de Recerca Sant Joan de Déu, Universitat Politècnica de Catalunya, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Institut Català de la Salut, Evidenze Health España SL (Spain), Generalitat de Catalunya, Departament de Salut, Novo Nordisk Pharma, SA (Spain), Universitat de Vic - Universitat Central de Catalunya, Hospital de Sant Pau, Institut de Recerca Sant Pau
Language: English
Subfield: Artificial Intelligence
Field: Computer Science
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $3,500
Funders: Centres de Recerca de Catalunya, Generalitat de Catalunya, Novo Nordisk, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Institut Català de la Salut, Instituto de Salud Carlos III, European Regional Development Fund, Departament de Salut, Generalitat de Catalunya, Agencia Estatal de Investigación
OpenAlex ID: W4407776331
